A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene

PLoS One. 2013 Apr 12;8(4):e61074. doi: 10.1371/journal.pone.0061074. Print 2013.

Abstract

Posterior cortical atrophy is a dementia syndrome with symptoms of cortical visual dysfunction, associated with amyloid plaques and neurofibrillary tangles predominantly affecting visual association cortex. Most patients diagnosed with posterior cortical atrophy will finally develop a typical Alzheimer's disease. However, there are a variety of neuropathological processes, which could lead towards a clinical presentation of posterior cortical atrophy. Mutations in the presenilin 1 gene, affecting the function of γ-secretase, are the most common genetic cause of familial, early-onset Alzheimer's disease. Here we present a patient with a clinical diagnosis of posterior cortical atrophy who harbors a novel Presenilin 1 mutation (I211M). In silico analysis predicts that the mutation could influence the interaction between presenilin 1 and presenilin1 enhancer-2 protein, a protein partner within the γ-secretase complex. These findings along with published literature support the inclusion of posterior cortical atrophy on the Alzheimer's disease spectrum.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Atrophy
  • Cerebral Cortex / pathology*
  • Cerebral Cortex / physiopathology
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Models, Molecular
  • Mutation / genetics*
  • Presenilin-1 / chemistry
  • Presenilin-1 / genetics*
  • Presenilin-1 / metabolism
  • Presenilin-2 / metabolism
  • Protein Binding
  • Tomography, Emission-Computed, Single-Photon
  • Vision, Ocular

Substances

  • Presenilin-1
  • Presenilin-2

Grants and funding

This work was partially supported by grant no N N401557840 from the Ministry of Science and Higher Education (Poland). EJS was supported by START Scholarship from the Foundation for Polish Science and a scholarship from the Ministry of Science and Higher Education (Poland). EP was supported by Foundation Stiftelsen Gamla Tjänarinnor, the Swedish Brain Fund, the Alzheimer Foundation, Sweden, and the Dementia Association, Sweden. DR was supported by Stiftelsen för ålderssjukdomar vid Karolinska Institutet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.